| 29093181 |
A precision therapy against cancers driven by KIT/PDGFRA mutations
Heinrich, MC,
Zhang, Y,
Hodous, BL,
Shutes, A,
Lengauer, C,
Evans, EK,
Kohl, N,
Wolf, B,
Schöffski, P,
Zhu, XJ,
Kim, JL,
Gebreyohannes, YK,
Gardino, AK,
Wozniak, A,
DiPietro, L,
Lydon, N,
Wilson, K,
Brooijmans, N,
Schmidt-Kittler, O,
Boral, A,
Miller, S,
LaBranche, TP,
Deangelo, DJ,
Davis, A,
Guzi, T,
Wilson, D
|
Sci Transl Med |
2017 |
| 31085175 |
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants
Hood, MM,
Gupta, A,
Su, Y,
Ensinger, CL,
Caldwell, TM,
Bulfer, SL,
Heinrich, MC,
Al-Ani, G,
Ahn, YM,
Patt, WC,
Janku, F,
Turner, BA,
Ruiz-Soto, R,
Leary, CB,
Abdul Razak, AR,
Yates, K,
Town, A,
Rosen, O,
Wise, SC,
Vogeti, L,
Telikepalli, H,
Rutkoski, TJ,
Vogeti, S,
Smith, BD,
Flynn, DL,
Chun, L,
Lu, WP,
Kaufman, MD,
McKinley, A
|
Cancer Cell |
2019 |
